Pyruvate kinase (PK) activation specialist Agios Pharmaceuticals Inc (Nasdaq:AGIO) announced on Wednesday that the US Food and Drug Administration (FDA) has granted orphan drug designation to tebapivat (AG-946), a novel PK activator, for the treatment of myelodysplastic syndromes (MDS).
This designation supports the development of tebapivat as a potential new treatment option for patients with this rare disease.
Agios completed a Phase 2a study of tebapivat in lower-risk MDS late last year and is currently initiating a Phase 2b study.
Mitapivat, the company's lead PK activator, was previously granted FDA orphan drug designation for the treatment of PK deficiency, thalassemia and sickle cell disease.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers